Abbonarsi

The impact of imidacloprid and its metabolites on long-term neurodevelopmental and neurodegenerative disorders in a Zebrafish model - 15/08/22

Doi : 10.1016/j.toxac.2022.06.234 
Megan Mcculloch , Lerato Homu, Carine Smith, Tracy Kellermann
 Clinical pharmacology, Stellenbosch university, Cape Town, South Africa 

Corresponding author.

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

Riassunto

Aim

This research aimed to assess the impact of lower dose, longer duration exposure of imidacloprid (IMI) on neurodevelopmental and neurodegenerative disorders in comparison to acute exposure within an in vivo zebrafish model. Sensitive, selective, accurate and efficient liquid chromatography tandem mass spectrometry (LC-MS/MS) methods were developed to quantitate bioaccumulation of IMI and its primary metabolites, as well as changes in neurotransmitter concentrations following IMI exposure. This study also assessed liver damage in response to imidacloprid administration as a measure of acute and chronic toxicity in a zebrafish larval model.

Introduction: IMI [1-(6-chloro-3-pyridylmethyl)-N-nitroimidazolidin-2-ylideneamine] is a systemic neonicotinoid insecticide belonging to the chloronicotinyl nitroguanidine chemical family produced to replace the organophosphorus pesticides in commercial agriculture (Crosby EB et al. Neurotoxicol Teratol [Internet]. 2015;49:81–90) (Kumar A et al, Egypt J Forensic Sci [Internet]. 2013;3(4):123–6). The extensive use of these pesticides increases the risk to biodiversity of freshwater aquatic surroundings due to their potential bioaccumulation and toxicity (Muazzam B et al, J Water Supply Res Technol-AQUA. 2019;68(8):718–30). While pesticide usage has economic benefits in large-scale agriculture, exposure can lead to detrimental effects on humans. Researchers studying the effect of IMI on human nicotinic receptors (α4β2) have reported that IMI may have more substantial side effects on humans than originally anticipated (Li P et al, J Neurosci Res. 2011;89(8):1295–301).

Method

Zebrafish larvae were exposed to IMI at 4 and 5 days post fertilisation to determine the no observed adverse effect level (NOAEL) of IMI. Behavioural activity tracking of the zebrafish larvae was monitored using Daniovision software. Oil red O was used to stain for fatty liver accumulation (steatosis) which is indicative of hepatotoxicity following IMI exposure. After this, adult zebrafish were exposed to the NOAEL concentration for 21 days. Key endpoints included developmental effects, behaviour indicative of neuropathology, neurodegeneration and possible bioaccumulation in the adult zebrafish tissues (brain and liver). Neurotransmitter concentrations were measured in the adult zebrafish brain tissue at the end of the treatment period to evaluate changes in neurotransmitter signalling and potential neurodevelopmental effects using a LC-MS/MS method. Bioaccumulation of IMI and its metabolites in zebrafish brain and liver was evaluated using LC-MS/MS.

Results

The NOAEL of IMI in zebrafish larvae was determined to be 2.5μg/L. Hepatotoxicity in the form of steatosis was observed in larvae subsequent to a 5-day treatment period. Adult zebrafish were exposed to the NOAEL IMI concentration for 21 days. No significant behavioural abnormalities were observed in the adult zebrafish during the treatment period. The calibration curve for the neurotransmitters fits a quadratic (weighted 1/C) regression over the concentration range of 3.906–1000ng/mL, 7.813–1000ng/mL, 15.625–1000ng/mL and 31.250–1000ng/mL for acetylcholine, serotonin, gamma-aminobutyric acid and dopamine, respectively. The calibration curve for IMI and its metabolites fits a quadratic (weighted 1/C) regression over the concentration range of 0.098–12.5ng/mL, 0.195–12.5ng/mL, 0.391–12.5ng/mL and 0.781–12.5ng/mL for desnitro-imidacloprid, imidacloprid, imidacloprid-urea and 5-hydro-imidacloprid, respectively.

Conclusion

Robust LC-MS/MS methods were developed for the quantitation of IMI, desnitro-imidacloprid, imidacloprid-urea and 5-hydro-imidacloprid, as well as serotonin, dopamine, acetylcholine and gamma-aminobutyric acid neurotransmitters in 200μl zebrafish brain and liver homogenate. These methods were used to observe changes in neurotransmitter signalling in response to low-level, long-term exposure to imidacloprid, even in the absence of behavioural changes. Furthermore, together with the evaluation of bioaccumulation of imidacloprid and its metabolites in the brain and liver of zebrafish, this study provides indications of impact on human health following chronic neonicotinoid exposure.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


© 2022  Pubblicato da Elsevier Masson SAS.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 34 - N° 3S

P. S140-S141 - Settembre 2022 Ritorno al numero
Articolo precedente Articolo precedente
  • Occurrence of GHB in blood and urine specimens from victims of alleged sexual assault or blackout in Western Switzerland
  • Caroline Mathon, Aurélien Thomas, Marc Augsburger
| Articolo seguente Articolo seguente
  • Automating DUID methods using robotics for rapid high throughput sample preparation – Section 4 and Section 5A UK Road Traffic Act Compounds in Whole Blood
  • Aaron Mcmillan, Mark Evans, Dionne Lawrence, Alongi Talia, Tian Bu, Mark Parkin, Grosse Susan

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.